Table 4.
Comparing incidence of skeletal metastases in prostate cancer and recommended cut-off levels of serum prostate-specific antigen in the prediction of metastases on bone scan in different studies
| Author(s) | Type of study | Study place | Study population (n) | Incidence of bone metastasis (%) | Cut-off value of Sr. PSA (ng/ml) |
|---|---|---|---|---|---|
| Lin et al.[11] | Retrospective | China | 703 | 15.08 | <20 |
| Ritenour et al.[12] | Retrospective | Georgia | 800 | 4 | >30 |
| Rhoden et al.[13] | Retrospective | Brazil | 214 | 16.3 | >20 |
| Sharma et al.[15] | Prospective observational | India | 89 | 48.3 | No threshold limit of Sr. PSA |
| Kamaleshwaran et al.[16] | Retrospective | India | 270 | 56 | <20 |
| Zaman et al.[17] | Retrospective | Pakistan | 204 | 33 | <10 |
| Present study | Retrospective | India | 292 | 59.58 | 29 |
Sr. PSA: Serum prostate-specific antigen